NTRK gene fusions in melanoma: detection, prevalence and potential therapeutic implications

Abstract excerpt

Fusions involving neurotrophic tyrosine receptor kinase (NTRK) are known drivers of oncogenesis and also occur in melanoma, although very rarely. A particularly high incidence of NTRK gene fusions is reported in infantile fibrosarcoma (> 90 %) or the secretory type of breast cancer (> 90 %). Recently, larotrectinib (a tropomyosin receptor kinase [TRK] inhibitor) was approved, and we wondered whether TRK...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cutaneous Melanoma Detection and Management
• Share to HER2/EGFR in Cancer Research
• Share to Melanoma and MAPK Pathways